Evotec AG today announced a strategic collaboration on induced pluripotent stem cell („iPSC“) technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-fraunhofer-ime-sp-sign-strategic-collaboration-on-ipsc-technology-5486
Evotec AG to report first half-year 2017 results on 10 August 2017
Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-first-half-year-2017-results-on-10-august-2017-5488
Ad hoc: Evotec AG to acquire Aptuit
Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC („Aptuit“) under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec’s role as leading player in integrated outsourced drug discovery and development solutions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-to-acquire-aptuit-5
Evotec to acquire Aptuit, expanding leadership in external innovation
Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-acquire-aptuit-expanding-leadership-in-external-innovation-5482
Evotec expands collaboration with STORM Therapeutics on its RNA epigenetic platform
Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics („STORM“) to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-storm-therapeutics-on-its-rna-epigenetic-platform-5480
Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance
Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-endometriosis-programme-into-phase-i-clinical-development-and-extend-alliance-5478
Evotec received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies
Evotec AG announced today that the Company has been awarded a ‚Programm für Innovation‘ („PROFI“) grant for a period of two years from the Hamburgische Investitions- und Förderbank Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-received-funding-from-ifb-hamburg-to-identify-antibody-mediated-t-cell-immunotherapies-5476
Evotec expands iPSC drug discovery leadership through strategic collaboration with Censo Biotechnologies
Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. („Censo“) to source and provide patient-derived induced pluripotent stem cells („iPSC“) to support Evotec’s broad iPSC platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-drug-discovery-leadership-through-strategic-collaboration-with-censo-biotechnologies-5474
LAB282 accelerates with second round funding
Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab282-accelerates-with-second-round-funding-5472
Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy
Evotec AG announced today that it will make a strategic investment as part of Facio Therapies‘ („Facio“) 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy („FSHD“) community (Total volume: EUR 4.8 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-strategic-investment-in-facio-therapies-to-support-development-of-novel-fshd-therapy-5470